Open AccessMultivitamin supplementation improves haematologic status in children born to HIV‐positive women in Tanzania
Author(s) -
Liu Enju,
Duggan Christopher,
Manji Karim P,
Kupka Roland,
Aboud Said,
Bosch Ronald J,
Kisenge Rodrick R,
Okuma James,
Fawzi Wafaie W
Publication year - 2013
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.7448/ias.16.1.18022
Subject(s) - medicine , multivitamin , placebo , breastfeeding , pediatrics , adverse effect , tanzania , nevirapine , vitamin , human immunodeficiency virus (hiv) , immunology , viral load , antiretroviral therapy , alternative medicine , environmental science , pathology , environmental planning
Anaemia is prevalent among children born to HIV‐positive women, and it is associated with adverse effects on cognitive and motor development, growth, and increased risks of morbidity and mortality. Objective To examine the effect of daily multivitamin supplementation on haematologic status and mother‐to‐child transmission (MTCT) of HIV through breastfeeding. Methods A total of 2387 infants born to HIV‐positive women from Dar es Salaam, Tanzania were enrolled in a randomized, double‐blind, placebo‐controlled trial, and provided a daily oral supplement of multivitamins (vitamin B complex, C and E) or placebo at age 6 weeks for 24 months. Among them, 2008 infants provided blood samples and had haemoglobin concentrations measured at baseline and during a follow‐up period. Anaemia was defined as haemoglobin concentrations<11 g/dL and severe anaemia<8.5 g/dL. Results Haemoglobin concentrations among children in the treatment group were significantly higher than those in the placebo group at 12 (9.77 vs. 9.64 g/dL, p= 0.03), 18 (9.76 vs. 9.57 g/dL, p= 0.004), and 24 months (9.93 vs. 9.75 g/dL, p= 0.02) of follow‐up. Compared to those in the placebo group, children in the treatment group had a 12% lower risk of anaemia (hazard ratio (HR): 0.88; 95% CI: 0.79–0.99; p= 0.03). The treatment was associated with a 28% reduced risk of severe anaemia among children born to women without anaemia (HR: 0.72; 95% CI: 0.56–0.92; p= 0.008), but not among those born to women with anaemia (HR: 1.10; 95% CI: 0.79–1.54; p= 0.57; p for interaction=0.007). One thousand seven hundred fifty three infants who tested HIV‐negative at baseline and had HIV testing during follow‐up were included in the analysis for MTCT of HIV. No association was found between multivitamin supplements and MTCT of HIV. Conclusions Multivitamin supplements improve haematologic status among children born to HIV‐positive women. Further trials focusing on anaemia among HIV‐exposed children are warranted in the context of antiretroviral therapy.